

IN THE CLAIMS:

BEST AVAILABLE COPY

Without prejudice, amend claims 16, 26 and 28 as follows:

201
16. (Twice Amended) A transdermal therapeutic system with a content of a first active ingredient, said first active ingredient comprising at least one of candesartan, its pharmaceutically suitable esters or salts.

202
26. (Twice Amended) The transdermal therapeutic system of claim 23 wherein the system is a matrix system comprising:

an impermeable covering layer;

at least one active ingredient-containing contact adhesive matrix layer or at least one ingredient-containing matrix layer coated with a contact adhesive;

a detachable protective layer; and

an active ingredient comprising at least one of candesartan, its pharmaceutically acceptable esters or salts.

203
28. (Twice Amended) The transdermal therapeutic system of claim 23 wherein the membrane system comprises:

an impermeable covering layer;

an active ingredient-containing reservoir or an active ingredient-containing reservoir layer;

a microporous or semipermeable membrane;

an optional contact adhesive layer; and

an active ingredient comprising at least one of candesartan, its pharmaceutically acceptable esters or salts.